$1.77
4.12% yesterday
Nasdaq, Dec 24, 10:10 pm CET
ISIN
US45782T1051
Symbol
INMB

Inmune Bio, Inc. Stock price

$1.77
+0.29 19.59% 1M
-4.84 73.22% 6M
-2.90 62.10% YTD
-2.72 60.58% 1Y
-5.26 74.82% 3Y
-10.98 86.12% 5Y
-6.22 77.85% 10Y
-6.22 77.85% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.07 4.12%
ISIN
US45782T1051
Symbol
INMB
Industry

Key metrics

Basic
Market capitalization
$47.1m
Enterprise Value
$19.3m
Net debt
positive
Cash
$27.7m
Shares outstanding
26.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
941.1 | 922.7
EV/Sales
386.5 | 379.0
EV/FCF
negative
P/B
1.9
Financial Health
Equity Ratio
81.1%
Return on Equity
-131.1%
ROCE
-197.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$50.0k | $51.0k
EBITDA
$-51.4m | -
EBIT
$-51.4m | $-50.1m
Net Income
$-49.9m | $-52.1m
Free Cash Flow
$-31.9m
Growth (TTM | estimate)
Revenue
25.0% | 410.0%
EBITDA
- | -
EBIT
-24.5% | -17.6%
Net Income
-21.2% | -23.7%
Free Cash Flow
-25.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-102,696.0% | -
EBIT
-102,752.0%
Net
-99,774.0% | -102,105.6%
Free Cash Flow
-63,796.0%
More
EPS
$-1.9
FCF per Share
$-1.2
Short interest
15.4%
Employees
18
Rev per Employee
$0.0
Show more

Is Inmune Bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Inmune Bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Inmune Bio, Inc. forecast:

8x Buy
67%
4x Hold
33%

Analyst Opinions

12 Analysts have issued a Inmune Bio, Inc. forecast:

Buy
67%
Hold
33%

Financial data from Inmune Bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.05 0.05
25% 25%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.23 9.23
6% 6%
18,460%
- Research and Development Expense 26 26
19% 19%
51,360%
-51 -51
-
-102,700%
- Depreciation and Amortization 0.03 0.03
-
60%
EBIT (Operating Income) EBIT -51 -51
24% 24%
-102,752%
Net Profit -50 -50
21% 21%
-99,780%

In millions USD.

Don't miss a Thing! We will send you all news about Inmune Bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inmune Bio, Inc. Stock News

Neutral
GlobeNewsWire
20 days ago
Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, announces a recently published overview of future applications and research areas for mesenchymal stromal cell (MSC) therapies, such as INmune's CORDStrom™ platform. The article, titled, “Fate and Function of Exogenously Administere...
Neutral
GlobeNewsWire
24 days ago
Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer's disease (AD) and elevated neuroinflammation. The results will be presented at t...
Neutral
GlobeNewsWire
about one month ago
Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on Alzheimer's Disease conference (CTAD), in San Diego, CA on December 1-4, 2025.
More Inmune Bio, Inc. News

Company Profile

INmune Bio, Inc. focuses on controlling components of the immune system to activate an immune response against cancer and Alzheimer's disease. Its product pipeline INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer, and LIVNATE. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.

Head office United States
CEO Raymond Tesi
Employees 18
Founded 2015
Website www.inmunebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today